PubMed 35. Visekruna A, Joeris T, Seidel D, Kroesen A, Loddenkemper C, Zeitz M, Kaufmann SH, Schmidt-Ullrich

R, Steinhoff U: Proteasome-mediated degradation of IkappaBalpha c-Met inhibitor and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 2006, 116:3195–3203.PubMedCrossRef 36. Gyrd-Hansen M, Meier P: IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010, 10:561–574.PubMedCrossRef 37. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285–296.PubMedCrossRef 38. Varfolomeev E, Vucic D: (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. Cell Cycle 2008, 7:1511–1521.PubMedCrossRef 39. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes K, Dixit VM, Vucic D: IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell

2007, 131:669–681.PubMedCrossRef 40. Vassiliou EK, Kesler OM, Tadros JH, Ganea D: Bone marrow-derived dendritic cells generated in the presence of resolvin E1 induce apoptosis of activated CD4+ T cells. J Immunol 2008, 181:4534–4544.PubMed 41. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN: Stereochemical assignment, antiinflammatory properties, LY2874455 manufacturer and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005, 201:713–722.PubMedCrossRef 42. Harpaz N, Polydorides AD: Colorectal dysplasia in chronic inflammatory bowel disease: pathology, clinical implications, and pathogenesis. Arch Pathol Lab Med 2010,

134:876–895.PubMed 43. Karin M: NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009, 1:a000141.PubMedCrossRef 44. Spehlmann ME, Eckmann L: Nuclear factor-kappa B in intestinal protection and destruction. Curr Opin Gastroenterol 2009, 25:92–99.PubMedCrossRef 45. Karrasch T, Jobin C: NF-kappaB and the intestine: friend or foe? Inflamm Bowel Dis 2008, 14:114–124.PubMedCrossRef oxyclozanide 46. Gadjeva M, Wang Y, Horwitz BH: NF-kappaB p50 and p65 subunits control intestinal homeostasis. Eur J Immunol 2007, 37:2509–2517.PubMedCrossRef 47. Schreiber S, Nikolaus S, Hampe J: Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998, 42:477–484.PubMedCrossRef 48. Ellis RD, Goodlad JR, Limb GA, Powell JJ, Thompson RP, GF120918 concentration Punchard NA: Activation of nuclear factor kappa B in Crohn’s disease. Inflamm Res 1998, 47:440–445.PubMedCrossRef 49. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Scholmerich J, Gross V: Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998, 115:357–369.PubMedCrossRef 50.